📄 medicine

Integrative 3D-QSAR and In Vitro Studies on Medicinal Plants Identify Bergenia ligulata

By integrating 3D-QSAR computational modeling with in vitro cytotoxicity assays, this study identifies *Bergenia ligulata* and its specific phytochemicals as promising, potent leads for the development of new therapeutic agents against bladder cancer.

Original authors: Ankita Sahu, Sahar Qazi, Ajeeshkumar Kizhakkeppurath Kumaran, Moshahid A. Rizvi, Khalid Raza, Saurabh Verma

Published 2026-08-07

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Ankita Sahu, Sahar Qazi, Ajeeshkumar Kizhakkeppurath Kumaran, Moshahid A. Rizvi, Khalid Raza, Saurabh Verma

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine the human body as a bustling city, and cancer as a rogue construction crew that refuses to stop building, tearing down healthy neighborhoods and taking over the landscape. Bladder cancer is one such chaotic crew, specifically hijacking the city's waste management system. For decades, doctors have tried to stop this crew with powerful synthetic weapons, but these can sometimes hurt the good citizens (healthy cells) along the way. This is where the ancient art of herbal medicine steps in, acting like a library of nature's own blueprints. Scientists are now using high-tech "digital magnifying glasses" called computer models to scan these blueprints. They look for specific shapes and chemical patterns that might fit perfectly into the cancer's locks, disabling the rogue crew without hurting the city. This process, known as QSAR (Quantitative Structure-Activity Relationship), is like a super-smart matchmaking service that predicts which natural ingredients are the best candidates to become future medicines before they ever touch a test tube.

In this study, a team of researchers decided to test this digital matchmaking idea against a real-world problem: bladder cancer. They started with a massive digital library containing 477 different chemical compounds found in four famous Ayurvedic plants: Bergenia ligulata (Pashanbheda), Aerva lanata (Badra), Boerhavia diffusa (Punarnava), and Tribulus terrestris (Gokshura). These plants have been used for centuries to treat urinary issues, and the researchers wondered if they could also fight cancer. First, they used computer software to filter out the "bad dates"—compounds that were too toxic, too hard to make, or just didn't fit the rules of being a good medicine. This left them with 160 promising candidates. They then ran a sophisticated 3D simulation (the QSAR model) to see which of these chemicals looked like they could best attack the cancer. The computer predicted that Bergenia ligulata was the star of the show, with a very strong mathematical link between its chemical structure and its ability to fight cancer.

But a computer prediction is just a theory until it's tested in the real world. So, the team took actual extracts from these four plants and pitted them against human bladder cancer cells (specifically the HT-1376 cell line) in a petri dish. They watched the cells over 48, 72, and 96 hours to see how many survived. The results were a perfect echo of the computer's prediction for Bergenia ligulata, which showed the most potent, time- and dose-dependent cytotoxicity among the aqueous extracts. However, the story was slightly more complex with the hydroalcoholic extracts. While Bergenia ligulata remained a strong contender, the hydroalcoholic extract of Tribulus terrestris actually emerged as the most potent killer in the lab, requiring the lowest dose to eliminate half the cells (an IC50 of just 103 µg/ml) after 96 hours. In contrast, Bergenia ligulata's hydroalcoholic extract required a higher dose (487 µg/ml) to achieve the same effect at that time point. The other two plants, Boerhavia diffusa and Aerva lanata, showed much weaker effects, requiring significantly higher doses to achieve similar results, and their performance didn't match the computer's high hopes as well as the top two contenders did.

The researchers also looked at the "face" of the dying cells under a microscope. When treated with the effective extracts, the cancer cells looked shriveled, clumped together, and formed dark, granular debris—classic signs of a cell giving up the fight. This visual evidence matched the numbers, confirming that the plant extracts were genuinely damaging the cancer cells. Interestingly, when they compared these natural extracts to standard chemotherapy drugs like Doxorubicin and Cisplatin, the drugs were still more potent at killing the cells, but the Bergenia ligulata and Tribulus terrestris extracts showed very promising levels of activity that suggest they could be valuable new leads.

The study didn't stop at just the whole plant extract. The computer model had identified specific "super-heroes" inside the plants that were likely doing the heavy lifting: eryodictiol-7-O-β-D-glucopyranoside, E-4-hepten-2-one, isorhamnetin, and quercetin were flagged as top candidates within Bergenia ligulata, while aervine was identified as a key compound in Aerva lanata. These are the specific chemical shapes the computer flagged as the most likely to be effective. The paper suggests that these specific compounds are the ones researchers should isolate and study further. However, the authors are careful to note that they haven't proven these compounds work in the human body yet, nor have they tested if they are safe for healthy cells. They are essentially saying, "We found a very strong clue in the computer and a very strong signal in the test tube, but the real work of turning these plants into a medicine is just beginning." The study concludes that Bergenia ligulata is the most promising lead based on the computational model and its aqueous extract performance, while Tribulus terrestris proved surprisingly potent in its hydroalcoholic form, offering a scientifically backed roadmap for future research to isolate active ingredients and potentially develop new, nature-based treatments for bladder cancer.

Technical Summary: Integrative 3D-QSAR and In Vitro Studies on Medicinal Plants Identify Bergenia ligulata as Promising Anticancer Leads against Bladder Cancer

Problem Statement
Bladder cancer represents a significant global health burden with rising incidence and complex biology, necessitating the discovery of novel therapeutic agents with reduced toxicity. While natural products from medicinal plants have historically provided approximately 60% of current anticancer drugs, the identification of specific active constituents from complex botanical sources remains a challenge. The authors posit that traditional Ayurvedic herbs used for urinary disorders—specifically Bergenia ligulata (Pashanbheda), Aerva lanata (Badra), Boerhavia diffusa (Punarnava), and Tribulus terrestris (Gokshura)—may possess anticancer potential due to their ability to alter urinary alkalinity, potentially countering the acidic microenvironments that fuel tumor growth. The study aims to bridge the gap between traditional ethnobotanical knowledge and modern drug discovery by integrating computational screening with targeted in vitro validation to identify leads for bladder cancer therapy.

Methodology
The study employed a tiered, integrative approach combining in silico computational modeling with in vitro biological assays:

In Silico Screening Pipeline:
- Dataset: 477 phytochemicals were retrieved from ChEMBL and PubChem for the four selected plants.
- ADMET Filtering: Using SwissADME and ProTox-II, compounds were screened for pharmacokinetic properties (solubility, lipophilicity, bioavailability), drug-likeness (Lipinski's Rule of 5, Veber's, Ghosh's, Muegge's, and Egan's rules), and toxicity. This reduced the library to 160 drug-like candidates.
- Biofilm Prediction: The Molib webserver was utilized to predict biofilm inhibition potential, further filtering the candidates.
- 3D-QSAR Modeling: From the filtered list, 40 top candidates (10 per plant) were selected for 3D-QSAR modeling using EasyQSAR. The dataset was split into a training set (70%) and a testing set (30%). Models were constructed using Partial Least Squares (PLS) regression with 5-fold cross-validation to evaluate predictive power ( $r^2$ and $q^2$ ).
In Vitro Validation:
- Extract Preparation: Aqueous and hydroalcoholic extracts were prepared from fresh plant materials.
- Cell Line: Human bladder carcinoma cells (HT-1376), derived from grade IV transitional cell carcinoma and grade III bladder carcinoma, were cultured.
- Cytotoxicity Assay: Cells were treated with varying concentrations (62.5–1000 µg/mL) of the extracts for 48, 72, and 96 hours. Viability was assessed using the Trypan Blue exclusion method.
- Morphological Analysis: Cell morphology was observed via inverted light microscopy and DAPI staining to visualize nuclear changes and cell death.
- Controls: Doxorubicin and Cisplatin were used as positive controls to benchmark cytotoxicity.

Key Results

Computational Findings:
- The 3D-QSAR model for Bergenia ligulata demonstrated superior predictive performance with a correlation coefficient ( $r^2$ ) of 0.8578 and a cross-validated coefficient ( $q^2$ ) of 0.868.
- In contrast, models for Aerva lanata, Boerhavia diffusa, and Tribulus terrestris showed poor correlation in testing sets, indicating lower reliability for predicting activity in those specific datasets.
- The Bergenia ligulata model identified five specific phytochemicals as top candidates: eryodictiol-7-O-β-D-glucopyranoside, E-4-hepten-2-one, isorhamnetin, quercetin, and aervine.
Experimental Findings:
- Bergenia ligulata: Exhibited the most potent, time- and dose-dependent cytotoxicity against HT-1376 cells.
  - Aqueous Extract IC50: 578 µg/mL (48h), 407 µg/mL (72h), and 210 µg/mL (96h).
  - Hydroalcoholic Extract IC50: 1736 µg/mL (48h), 1708 µg/mL (72h), and 487 µg/mL (96h).
  - Microscopy confirmed dose-dependent cell death, characterized by black granular debris and reduced cell numbers.
- Other Plants: Aerva lanata, Boerhavia diffusa, and Tribulus terrestris showed significantly weaker cytotoxicity. Notably, Tribulus terrestris hydroalcoholic extract showed moderate activity (IC50 ~103 µg/mL at 96h), but Bergenia ligulata remained the most consistent lead across both extract types and time points.
- Standard Drugs: Doxorubicin and Cisplatin demonstrated high potency (IC50 values ranging from ~16–36 µg/mL), serving as effective benchmarks.

Significance and Claims
The authors claim that the integration of 3D-QSAR prediction with cell-based validation successfully identified Bergenia ligulata as a priority source of anticancer phytochemicals for bladder cancer. The study highlights a concordance between computational predictions (high $r^2$ and $q^2$ values) and empirical observations (potent cytotoxicity), validating the utility of this in-silico triage strategy for prioritizing ethnobotanical leads.

The paper asserts that the identified phytochemicals (eryodictiol-7-O-β-D-glucopyranoside, isorhamnetin, quercetin, and aervine) possess favorable pharmacokinetic and pharmacodynamic properties, suggesting they could serve as therapeutic agents. However, the authors maintain a modest stance regarding immediate clinical application. They explicitly state that the current findings justify bioactivity-guided fractionation to isolate active constituents, followed by mechanistic studies (apoptosis, cell-cycle profiling) and in vivo validation. The study does not claim these extracts are ready for clinical use but rather provides a scientifically justified roadmap for advancing specific phytochemical leads toward preclinical development.

Limitations Acknowledged
The authors note that the use of crude extracts means observed potency may result from synergistic effects or be masked by antagonists. Furthermore, the effective concentrations are relatively high compared to small-molecule therapeutics, necessitating further purification and optimization. Selectivity against non-malignant cells and in vivo pharmacokinetics remain untested.

Technical Summary: Integrative 3D-QSAR and In Vitro Studies on Medicinal Plants Identify Bergenia ligulata as Promising Anticancer Leads against Bladder Cancer

More like this